Zura Bio Ltd (ZURA) company profile
Close on Nov 19, 2026Market cap $91.74MP/E –Yield –
About Zura Bio
Biological Products, (No Diagnostic Substances), SIC 2836
Zura Bio is a clinical-stage biotechnology company focused on developing therapies for individuals suffering from autoimmune and inflammatory disorders. The company’s pipeline comprises three licensed drug candidates: tibulizumab, a bispecific antibody designed to inhibit both IL-17A and BAFF; crebankitug, a monoclonal antibody targeting IL-7 receptor alpha; and torudokimab, a monoclonal antibody directed against IL-33. Rather than serving commercial customers, the firm evaluates its experimental treatments in adult clinical trial participants, with tibulizumab undergoing evaluation for hidradenitis suppurativa and diffuse cutaneous systemic sclerosis.
The company operates without dedicated in-house facilities, instead relying on contract manufacturers across Italy, the Netherlands, and the United Kingdom, alongside stability studies in China, to produce drug substance and drug product batches. Clinical studies take place across the United States, Canada, Europe, and Latin America, involving over three hundred targeted participants across active Phase 2 programs. The provided text does not identify the location of the corporate headquarters.
Summary of the business section of Zura Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zura Bio Ltd
- Headquarters
- La Jolla, CA
- Address
- 4225 Executive Square, Suite 600 92037
- Phone
- (858) 247-0520
- Website
- zurabio.com
- Employees
- 40, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- WithumSmith+Brown, PC, East Brunswick, New Jersey
Stock & identifiers
- Ticker
- ZURA
- Former tickers
- JATT until Mar 21, 2023
- Exchange
- Nasdaq
- IPO date
- Jul 14, 2021
- Shares outstanding
- 96M, Oct 27, 2026
- Public float
- $58.99M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1855644
- CUSIP
- G9TY5A101
- FIGI
- BBG011FJXV49
- Share class FIGI
- BBG011FJXVZ5
- LEI
- 549300LQXD6M2MIQFN24
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sandeep Chidambar Kulkarni | Chief Executive Officer, Director | – |
| Robert Lisicki | Chief Executive Officer, Director | – |
| Marlyn Teresa Mathew | VP, Principal Acctg. Officer | 129,182 |
| Gary Whale | Chief Technology Officer | – |
| Eric J. Hyllengren | Chief Financial Officer | – |
| Kim Davis | Chief Legal Officer | 493,881 |
| Kiran Nistala | See Remarks | 3,195 |
| Verender S. Badial | Chief Financial Officer | 517,519 |
| Daniel J. Becker | Director | – |
| Mark Eisner | Director | – |
| Ajay Nirula | Director | – |
| Jennifer Jarrett | Director | – |
| Amit Munshi | Director | 777,384 |
| Steven J. Schoch | Director | – |
| Parvinder Thiara | Director | 0 |
| van Amstel Arnout Ploos | Director | 120,000 |
| Neil Murray Hamilton Graham | Director | – |
| Someit Sidhu | Director | 5,203,715 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Robert Lisicki Former Chief Executive Officer | $624.00K | – | $1.12M | – | $1.74M | -74% |
| Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary; Former Interim Chief Executive Officer | $486.36K | $312.00K | $474.09K | $8.84K | $1.28M | -29% |
| Eric Hyllengren Former Chief Financial Officer | $230.30K | $95.00K | $711.31K | $11.88K | $1.05M | – |
| Kiran Nistala Chief Medical Officer and Head of Development | $468.33K | $213.41K | $331.42K | $9.41K | $1.02M | -60% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Jul 14, 2021
- Offer price
- $10.00
- Securities offered
- 12,000,000
- Gross proceeds
- $120.00M
- Exchange
- NYSE
- First trading day
- Sep 3, 2021
- First-day close
- $9.70-3.0%
- Lock-up ends (est.)
- Mar 2, 2022
“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 40 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 27, 2024 | Delisting | Notice of delisting from exchange (Form 25) |
| Jul 12, 2024 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 23, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Mar 24, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 21, 2023 | Name change | Name changed from JATT Acquisition Corp to Zura Bio Ltd |
| Mar 20, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 20, 2023 | Delisting | Notice of delisting from exchange (Form 25) |
| Aug 22, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 31, 2022 | Late filing | Notification of late filing |
| Nov 15, 2021 | Late filing | Notification of late filing |
| Jul 14, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 13, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?